Eco Animal Health Group PLC Partnership with Imperial College (9411O)
June 15 2022 - 2:35AM
UK Regulatory
TIDMEAH
RNS Number : 9411O
Eco Animal Health Group PLC
15 June 2022
13 June 2022
ECO Animal Health Group plc
("ECO", the "Company" or the "ECO Group") (AIM: EAH)
Partnership with Imperial College London
saRNA technology to deliver swine vaccines and biologics
ECO Animal Health Group plc, a leader in the development,
registration and marketing of pharmaceutical products for global
animal health markets, is pleased to announce that its wholly owned
subsidiary, ECO Animal Health Ltd, has entered into a research
partnership with Professor Robin Shattock at Imperial College
London, to assess the veterinary application of the novel
self-amplifying RNA (saRNA) technology. The scope of the
collaboration will be the delivery of vaccine antigens and
biologics to pigs against three important infectious disease
targets (two viral and one bacterial).
saRNA is a new platform for the development of medicines and
vaccines which uses similar technology to mRNA but with the added
ability to self-amplify, thereby expressing proteins for a longer
time period, resulting in higher protein levels per dose. This has
the potential to allow saRNAs to be delivered at lower
concentrations than conventional mRNA therapeutics, leading to less
frequent or lower dosing, lower costs and a much broader range of
potential applications. The saRNA platform aims to underpin the
next generation of RNA-delivered medicines enabling not only
vaccines but also a broad range of therapeutic applications, for
example conditions where immune modulation is beneficial.
ECO will use its validated swine disease models to generate
proof of concept data within one year, with the view of selecting
candidates for development, registration and commercialisation
under license from Imperial College London.
The diseases targeted with this technology are among the most
economically damaging to the swine industry which amounts to nearly
800 million pigs worldwide and represents 36% of total meat
consumption.
David Hallas, Chief Executive of ECO said : "This is a very
exciting collaboration for ECO and a great credit to our R&D
team for having successfully concluded the agreement with Imperial
College. The global market potential for products developed from
this partnership is very significant and, if successful, would be a
major step in ECO's longer term strategy to develop new and
innovative products alongside Aivlosin."
Professor Robin Shattock of Imperial College said : "I am
pleased to be working with the team at ECO on this exciting
project. saRNA technology has very significant potential in animal
health as it can be delivered in much lower doses than is currently
possible and hence represents the next generation of RNA delivered
medicines."
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part
of United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via a Regulatory Information Service ("RIS"), this inside
information is now considered to be in the public domain.
For further information please contact:
ECO Animal Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO) 020 8447 8899
IFC Advisory
Graham Herring
Zach Cohen 020 3934 6630
Singer Capital Markets (Nominated Adviser
& Joint Broker)
Mark Taylor
George Tzimas 020 7496 3000
Investec (Joint Broker)
Gary Clarence
Alex Penney 020 7597 5970
Carlo Spingardi
Peel Hunt LLP (Joint Broker)
Dr Christopher Golden
James Steel 020 7418 8900
Equity Developments
Hannah Crowe
Matt Evans 020 7065 2692
About ECO Animal Health
ECO Animal Health Group plc researches, develops and
commercialises products for livestock. Our business strategy is to
generate shareholder value by achieving the maximum sales potential
from the existing product portfolio whilst investing in Research
and Development ("R&D") for new products, particularly
vaccines, and seeking to in-license new products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFFSMIEESEDM
(END) Dow Jones Newswires
June 15, 2022 02:35 ET (06:35 GMT)
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Apr 2023 to Apr 2024